Domain Associates, a venture capital firm that invests in life sciences technologies, said on Wednesday that it has promoted Nimesh Shah to partner. Prior to working at Domain, Nimesh was part of the investment team at the venture firm, Cutlass Capital and a member of the medical device research team at Alex. Brown & Sons (now Deutsche Bank).
PRINCETON, N.J. and SAN DIEGO, June 12, 2013 /PRNewswire/ — Domain Associates, a U.S. venture capital firm investing in breakthrough life sciences technologies, announced today that Nimesh Shah has been promoted to partner. He joined Domain in 2006.
“Nimesh has been instrumental at Domain in driving opportunities in the rapidly evolving medical device space,” said Brian Dovey, partner at Domain Associates. “He brings a depth of knowledge to and works closely with our entrepreneurs and management teams to build the next generation of great device companies.”
“Working with entrepreneurs means that you are working with people who are passionate about what they do,” said Nimesh Shah. “It’s hard not to be equally infected with the same level of enthusiasm, especially to be able to do so in such a dynamic environment.”
Nimesh is a co-founder and board member of Zyga Technology and is a board member of Benvenue Medical, Cotera, Miramar Labs, Sequent Medical, and Twelve (Foundry Newco VII). He also serves as a board observer at ReVision Optics and Tandem Diabetes Care. Nim is also involved with The Foundry, a medical devices incubator. He currently serves on the Dean’s Leadership Council for the UCSD School of Biological Sciences and as a board member for the San Diego Venture Group.
Prior to Domain, Nimesh was part of the investment team at the venture firm, Cutlass Capital, and a member of the medical device research team at Alex. Brown & Sons (now Deutsche Bank). Nimesh received his degree in biomedical engineering from the Johns Hopkins University.
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on investing in life science companies that advance human health. Domain’s focused network, deep experience, and dependable reputation of this team have made it one of the top private-equity groups participating in healthcare investing. With more than $2.7 billion in capital raised, Domain invests in three major segments: pharmaceuticals, diagnostics, and medical devices. The partners of Domain have a total of more than 270 person-years of experience among them in the healthcare and venture capital industries and have been involved in the formation and growth of more than 250 life sciences companies. Representative past investments include Amgen, Amylin Pharmaceuticals, Cerexa, Biosite, Dura Pharmaceuticals, Pharmion and Volcano. Domain has offices in Princeton, N.J. and San Diego. For more information, please visit http://www.domainvc.com.